Reevaluating the Risk of Serious Adverse Events of Carbonic Anhydrase Inhibitors
- PMID: 35616947
- DOI: 10.1001/jamaophthalmol.2022.1565
Reevaluating the Risk of Serious Adverse Events of Carbonic Anhydrase Inhibitors
Comment in
-
Reevaluating the Risk of Serious Adverse Events of Carbonic Anhydrase Inhibitors-Reply.JAMA Ophthalmol. 2022 Jul 1;140(7):746-747. doi: 10.1001/jamaophthalmol.2022.1568. JAMA Ophthalmol. 2022. PMID: 35616951 No abstract available.
Comment on
-
Serious Adverse Events of Oral and Topical Carbonic Anhydrase Inhibitors.JAMA Ophthalmol. 2022 Mar 1;140(3):235-242. doi: 10.1001/jamaophthalmol.2021.5977. JAMA Ophthalmol. 2022. PMID: 35084437 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
